Carisma Therapeutics Inc. (NASDAQ:CARM) — Market Cap & Net Worth
Market Cap & Net Worth: Carisma Therapeutics Inc. (CARM)
Carisma Therapeutics Inc. (NASDAQ:CARM) has a market capitalization of $20.92K ($20.92K) as of May 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #31228 globally and #5995 in its home market, demonstrating a -50.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Carisma Therapeutics Inc.'s stock price $0.00 by its total outstanding shares 41845078 (41.85 Million). Analyse Carisma Therapeutics Inc. operating cash flow efficiency to see how efficiently the company converts income to cash.
Carisma Therapeutics Inc. Market Cap History: 2015 to 2026
Carisma Therapeutics Inc.'s market capitalization history from 2015 to 2026. Data shows change from $2.14 Billion to $20.92K (-66.24% CAGR).
Index Memberships
Carisma Therapeutics Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #931 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2922 of 3165 |
Weight: Carisma Therapeutics Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Carisma Therapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Carisma Therapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.89x
Carisma Therapeutics Inc.'s market cap is 0.89 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.14 Billion | $990.00K | -$33.45 Million | 2163.99x | N/A |
| 2016 | $1.36 Billion | $29.98 Million | $1.89 Million | 45.34x | 718.89x |
| 2017 | $577.22 Million | $425.00K | -$29.03 Million | 1358.17x | N/A |
| 2020 | $960.85 Million | $11.24 Million | -$28.35 Million | 85.52x | N/A |
| 2021 | $580.07 Million | $26.54 Million | -$336.00K | 21.85x | N/A |
| 2022 | $433.81 Million | $9.83 Million | -$61.23 Million | 44.11x | N/A |
| 2023 | $122.61 Million | $14.92 Million | -$86.88 Million | 8.22x | N/A |
| 2024 | $17.52 Million | $19.63 Million | -$60.48 Million | 0.89x | N/A |
Competitor Companies of CARM by Market Capitalization
Companies near Carisma Therapeutics Inc. in the global market cap rankings as of May 3, 2026.
Key companies related to Carisma Therapeutics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Carisma Therapeutics Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, Carisma Therapeutics Inc.'s market cap moved from $2.14 Billion to $ 20.92K, with a yearly change of -66.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $20.92K | -98.84% |
| 2025 | $1.80 Million | -89.73% |
| 2024 | $17.52 Million | -85.71% |
| 2023 | $122.61 Million | -71.74% |
| 2022 | $433.81 Million | -25.21% |
| 2021 | $580.07 Million | -39.63% |
| 2020 | $960.85 Million | +29.81% |
| 2019 | $740.21 Million | -26.76% |
| 2018 | $1.01 Billion | +75.09% |
| 2017 | $577.22 Million | -57.54% |
| 2016 | $1.36 Billion | -36.54% |
| 2015 | $2.14 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Carisma Therapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.92K USD |
| MoneyControl | $20.92K USD |
| MarketWatch | $20.92K USD |
| marketcap.company | $20.92K USD |
| Reuters | $20.92K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Carisma Therapeutics Inc.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced… Read more